TAHO Pharmaceuticals Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy 2025-10-01 14:16
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant 2025-02-17 21:03
TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant 2025-01-21 15:30
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects 2024-11-19 14:08
1